Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic
The novel coronavirus 2019 (COVID-19) and the subsequent pandemic present a challenge to neurologists treating patients with multiple sclerosis (MS) worldwide. Many national professional bodies have responded rapidly by issuing guidelines for the COVID-19 pandemic, primarily focused on MS disease-m...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Vilnius University Press
2020-06-01
|
| Series: | Neurologijos seminarai |
| Subjects: | |
| Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27741 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593050988183552 |
|---|---|
| author | R. Kizlaitienė N. Giedraitienė I. Sereikė J. Liutkienė L. Leščinskienė G. Kaubrys |
| author_facet | R. Kizlaitienė N. Giedraitienė I. Sereikė J. Liutkienė L. Leščinskienė G. Kaubrys |
| author_sort | R. Kizlaitienė |
| collection | DOAJ |
| description |
The novel coronavirus 2019 (COVID-19) and the subsequent pandemic present a challenge to neurologists treating patients with multiple sclerosis (MS) worldwide. Many national professional bodies have responded rapidly by issuing guidelines for the COVID-19 pandemic, primarily focused on MS disease-modifying therapies (DMTs). In this article, we review implications of COVID-19 for people with MS, including general health advice, the risk of respiratory infections, basic recommendations for relapse management, MS treatment, including disease-modifying therapies, and medical services for MS patients during the COVID-19 pandemic.
|
| format | Article |
| id | doaj-art-125cdc4beeae4217aaf68f8afb0f37d1 |
| institution | Kabale University |
| issn | 1392-3064 2424-5917 |
| language | English |
| publishDate | 2020-06-01 |
| publisher | Vilnius University Press |
| record_format | Article |
| series | Neurologijos seminarai |
| spelling | doaj-art-125cdc4beeae4217aaf68f8afb0f37d12025-01-20T18:22:46ZengVilnius University PressNeurologijos seminarai1392-30642424-59172020-06-01242(84)10.29014/ns.2020.13Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemicR. Kizlaitienė 0N. Giedraitienė 1I. Sereikė 2J. Liutkienė 3L. Leščinskienė 4G. Kaubrys 5Vilnius University, LithuaniaVilnius University, LithuaniaVilnius University, LithuaniaVilnius University, LithuaniaVilnius University, LithuaniaVilnius University, Lithuania The novel coronavirus 2019 (COVID-19) and the subsequent pandemic present a challenge to neurologists treating patients with multiple sclerosis (MS) worldwide. Many national professional bodies have responded rapidly by issuing guidelines for the COVID-19 pandemic, primarily focused on MS disease-modifying therapies (DMTs). In this article, we review implications of COVID-19 for people with MS, including general health advice, the risk of respiratory infections, basic recommendations for relapse management, MS treatment, including disease-modifying therapies, and medical services for MS patients during the COVID-19 pandemic. https://www.journals.vu.lt/neurologijos_seminarai/article/view/27741COVID-19 pandemicmultiple sclerosisdisease-modifying therapies |
| spellingShingle | R. Kizlaitienė N. Giedraitienė I. Sereikė J. Liutkienė L. Leščinskienė G. Kaubrys Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic Neurologijos seminarai COVID-19 pandemic multiple sclerosis disease-modifying therapies |
| title | Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic |
| title_full | Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic |
| title_fullStr | Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic |
| title_full_unstemmed | Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic |
| title_short | Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic |
| title_sort | recommendations for the treatment of multiple sclerosis with disease modifying drugs during the covid 19 pandemic |
| topic | COVID-19 pandemic multiple sclerosis disease-modifying therapies |
| url | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27741 |
| work_keys_str_mv | AT rkizlaitiene recommendationsforthetreatmentofmultiplesclerosiswithdiseasemodifyingdrugsduringthecovid19pandemic AT ngiedraitiene recommendationsforthetreatmentofmultiplesclerosiswithdiseasemodifyingdrugsduringthecovid19pandemic AT isereike recommendationsforthetreatmentofmultiplesclerosiswithdiseasemodifyingdrugsduringthecovid19pandemic AT jliutkiene recommendationsforthetreatmentofmultiplesclerosiswithdiseasemodifyingdrugsduringthecovid19pandemic AT llescinskiene recommendationsforthetreatmentofmultiplesclerosiswithdiseasemodifyingdrugsduringthecovid19pandemic AT gkaubrys recommendationsforthetreatmentofmultiplesclerosiswithdiseasemodifyingdrugsduringthecovid19pandemic |